• MabVax Therapeutics (MBVX) Phase 1 Results of MVT-5873 for Pancreatic Cancer

       (0 reviews)

    Biotech_Forecast
    Clinical and Regulatory
    Event Type: Phase 1 Results
    Timing: Q4 2016
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Oncology
    Indication: Pancreatic Cancer
    Lead Indication?: Yes
    Treatment Name: MVT-5873

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: MabVax Therapeutics
    Stock Symbol: MBVX
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://www.mabvax.com/resources/Shareholder%20Letter%20September%202016.pdf
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

    Quote

    We have stated that in the third quarter we will be providing a progress report on the clinical programs and announcing interim results from the Phase 1 clinical trial for our clinical development product MVT-5873 for the treatment of pancreatic cancer before the end of the year. We are highly encouraged by the progress thus far and anticipate very meaningful results to be disclosed in this timeframe.

     


      Report Event


    User Feedback

    There are no reviews to display.